Hosted on MSN1mon
Blue Lake Biotechnology sees success in early RSV vaccine results
US-based clinical-stage intranasal vaccine company, Blue Lake Biotechnology’s pediatric nasal vaccine for respiratory syncytial virus (RSV), BLB201, was safe and effective for paediatric ...
Business Wire1mon
Blue Lake Biotechnology Reports Additional Promising Clinical Data from Ongoing Pediatric Clinical Study of Intranasal RSV Vaccine BLB201
ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness ...
bluebird bio Q4 EPS Estimate Increased by Leerink Partnrs
Research analysts at Leerink Partnrs upped their Q4 2024 earnings estimates for shares of bluebird bio in a research report issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now ...